144 related articles for article (PubMed ID: 29260621)
1. Immunologic treatment of Parkinson's disease.
Jankovic J
Immunotherapy; 2018 Feb; 10(2):81-84. PubMed ID: 29260621
[No Abstract] [Full Text] [Related]
2. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
George S; Brundin P
J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.
Brys M; Fanning L; Hung S; Ellenbogen A; Penner N; Yang M; Welch M; Koenig E; David E; Fox T; Makh S; Aldred J; Goodman I; Pepinsky B; Liu Y; Graham D; Weihofen A; Cedarbaum JM
Mov Disord; 2019 Aug; 34(8):1154-1163. PubMed ID: 31211448
[TBL] [Abstract][Full Text] [Related]
5. T cells from patients with Parkinson's disease recognize α-synuclein peptides.
Sulzer D; Alcalay RN; Garretti F; Cote L; Kanter E; Agin-Liebes J; Liong C; McMurtrey C; Hildebrand WH; Mao X; Dawson VL; Dawson TM; Oseroff C; Pham J; Sidney J; Dillon MB; Carpenter C; Weiskopf D; Phillips E; Mallal S; Peters B; Frazier A; Lindestam Arlehamn CS; Sette A
Nature; 2017 Jun; 546(7660):656-661. PubMed ID: 28636593
[TBL] [Abstract][Full Text] [Related]
6. Roles for the adaptive immune system in Parkinson's and Alzheimer's diseases.
Lindestam Arlehamn CS; Garretti F; Sulzer D; Sette A
Curr Opin Immunol; 2019 Aug; 59():115-120. PubMed ID: 31430650
[TBL] [Abstract][Full Text] [Related]
7. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
[TBL] [Abstract][Full Text] [Related]
8. Autoimmunity in Parkinson's Disease: The Role of α-Synuclein-Specific T Cells.
Garretti F; Agalliu D; Lindestam Arlehamn CS; Sette A; Sulzer D
Front Immunol; 2019; 10():303. PubMed ID: 30858851
[TBL] [Abstract][Full Text] [Related]
9. Enzyme-linked immunosorbent assays for α-synuclein with species and multimeric state specificities.
Lee HJ; Bae EJ; Jang A; Ho DH; Cho ED; Suk JE; Yun YM; Lee SJ
J Neurosci Methods; 2011 Aug; 199(2):249-57. PubMed ID: 21658411
[TBL] [Abstract][Full Text] [Related]
10. [Disease-Modifying Therapy for Parkinson's Disease].
Shimura H; Hattori N
Brain Nerve; 2017 Feb; 69(2):159-165. PubMed ID: 28202824
[TBL] [Abstract][Full Text] [Related]
11. First therapy targeting Parkinson's proteins enters clinical trials.
Dolgin E
Nat Med; 2012 Jul; 18(7):992-3. PubMed ID: 22772533
[No Abstract] [Full Text] [Related]
12. ELISA method to detect α-synuclein oligomers in cell and animal models.
Lassen LB; Gregersen E; Isager AK; Betzer C; Kofoed RH; Jensen PH
PLoS One; 2018; 13(4):e0196056. PubMed ID: 29698510
[TBL] [Abstract][Full Text] [Related]
13. Clinical Trial Highlights: Targetting Alpha-Synuclein.
McFarthing K; Simuni T
J Parkinsons Dis; 2019; 9(1):5-16. PubMed ID: 30741694
[No Abstract] [Full Text] [Related]
14. Immunotherapies for Parkinson's Disease: Progression of Clinical Development.
Teng JS; Ooi YY; Chye SM; Ling APK; Koh RY
CNS Neurol Disord Drug Targets; 2021; 20(9):802-813. PubMed ID: 34042040
[TBL] [Abstract][Full Text] [Related]
15. Parkinson disease: A monoclonal antibody targeting misfolded α-synuclein has therapeutic potential in Parkinson disease.
Wood H
Nat Rev Neurol; 2014 Aug; 10(8):426. PubMed ID: 25002110
[No Abstract] [Full Text] [Related]
16. Sticking it to Parkinson's disease.
Leslie M
Sci Aging Knowledge Environ; 2005 Jun; 2005(25):nf46. PubMed ID: 15975896
[No Abstract] [Full Text] [Related]
17. Intrabody and Parkinson's disease.
Zhou C; Przedborski S
Biochim Biophys Acta; 2009 Jul; 1792(7):634-42. PubMed ID: 18834937
[TBL] [Abstract][Full Text] [Related]
18. Development of Passive Immunotherapies for Synucleinopathies.
Bergström AL; Kallunki P; Fog K
Mov Disord; 2016 Feb; 31(2):203-13. PubMed ID: 26704735
[TBL] [Abstract][Full Text] [Related]
19. Immunization therapies for Parkinson's disease: state of the art and considerations for future clinical trials.
Antonini A; Bravi D; Sandre M; Bubacco L
Expert Opin Investig Drugs; 2020 Jul; 29(7):685-695. PubMed ID: 32419521
[TBL] [Abstract][Full Text] [Related]
20. Vaccination for Parkinson's disease.
Schneeberger A; Mandler M; Mattner F; Schmidt W
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S11-3. PubMed ID: 22166404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
